NASDAQ · AMRX

Amneal Pharmaceuticals, Inc.

$18.09 +$0.17 (+0.95%) 1D After hours
Charting by TradingView

Key Metrics

$5.72B
Market cap
46.86×
P/E · TTM
$3.05B
Revenue · TTM
$122.12M
Net income
EPS · TTM $0.38
Dividend yield —
Free cash flow $240.77M
Beta · 1Y 0.73
EBITDA · TTM —
Gross margin 38.7%

Snapshot

Market cap$5.72B
Enterprise value$8.10B
Shares outstanding319.3M
52-wk range$7.67 – $18.39
Avg volume · 20D1.4M
Net cash −$2.37B
Book value / share$-0.14
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Amneal Pharmaceuticals, Inc.
IPO dateMay 7, 2018
Employees8500

Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E46.86
P/S1.88
P/FCF23.77
EV/EBITDA—
EV/Sales2.66
Graham №—

Profitability

Gross 38.7%
Operating 6.0%
Net 4.0%
FCF 7.9%
ROE / ROIC -157.9% · 7.8%

Financial Health

Current ratio2.47
Quick ratio1.59
Debt / equity-56.63
Debt / EBITDA —
Net cash −$2.37B
Working capital$1.07B

Cash Flow · TTM

Operating CF $305.84M
Capex −$65.08M
Free cash flow $240.77M
Buybacks —
Dividends paid —
Shareholder yield —

Piotroski F-Score

7 / 9
Strong fundamentals · 7 of 9 signals passing

Altman Z-Score

—
Insufficient balance-sheet inputs

Graham Number vs Price

—
Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings